Oral Cancer News | Tag Archive

Erlotinib dose doubled for smokers with head/neck cancer

Saturday, January 28, 2012

Source: www.oncologyreport.com Author: Miriam E. Tucker Giving smokers a higher, short-course dose of erlotinib before definitive surgery for squamous cell carcinoma of the head and neck resulted in favorable responses for the first patients evaluated in a small pilot study. Investigators gave 300 mg of erlotinib (Tarceva) to smokers daily and 150 mg daily to [...]

Roche scientist provides a look at drugmaker’s early pipeline

Monday, January 2, 2012

0 Comments

Source: www.nj.com/ Author: Susan Todd/The Star-Ledger Jean-Jacques Garaud, who heads Roche’s pharmaceutical research and early development efforts in Switzerland, visited the drugmaker’s Nutley campus in mid-December and spent some time speaking with The Star-Ledger about the company’s efforts in the laboratory. The talk with Garaud provided a rare glimpse of the giant Swiss drugmaker’s early-stage [...]

Yale School of Medicine Researchers take a closer look at “smart drugs”

Thursday, May 19, 2011

0 Comments

Source: Yale University Some of the most effective and expensive cancer drugs, dubbed “smart drugs” for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor (EGFR), and found that [...]

‘Synthetic lethality’ strategy improves molecularly targeted cancer therapy

Tuesday, September 21, 2010

0 Comments

Source: www.physorg.com Author: Fox Chase Cancer Center Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells [...]

ASCO: Antibody improves head and neck cancer results

Sunday, June 6, 2010

0 Comments

Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel antibody improved outcomes for patients with advanced and inoperable squamous cell carcinoma of the head and neck, researchers reported. Combined with radiation or chemoradiation, the substance — a fully humanized monoclonal antibody dubbed nimotuzumab — significantly outperformed either modality alone in an open-label [...]

Nano-bio-chip sensor platform for examination of oral exfoliative cytology

Sunday, April 4, 2010

0 Comments

Source: Cancer Prevention Research 3(4); 518-28, March 23, 2010 Authors: SE Weigum et al. Oral cancer is a deadly and disfiguring disease that could greatly benefit from new diagnostic approaches enabling early detection. In this pilot study, we describe a nano-bio-chip (NBC) sensor technique for analysis of oral cancer biomarkers in exfoliative cytology specimens, targeting [...]

Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer

Monday, March 22, 2010

0 Comments

Source: 7thspace.com/headlines Author: staff Many cancerous cells accumulate beta-catenin in the nucleus. We examined the role of epidermal growth factor receptor (EGFR) signaling in the accumulation of beta-catenin in the nuclei of oral cancer cells. Results: We used two strains of cultured oral cancer cells, one with reduced EGFR expression (OECM1 cells) and one with [...]

New DNA therapy for advanced mouth cancer

Sunday, February 7, 2010

0 Comments

Source: www.dentistry.co.uk Author: staff A research team has been awarded a patent after developing a new DNA therapy for head and neck cancer sufferers. Researchers from the University of Pittsburgh School of Medicine in the US, aims to develop a safe and effective alternative to standard chemotherapy treatments which cause debilitating side-effects. Based on a [...]

Pitt researchers receive patent for new head and neck cancer treatment

Sunday, January 31, 2010

0 Comments

Source: www.healthcanal.com Author: staff Researchers from the University of Pittsburgh School of Medicine have been awarded a patent from the U.S. Patent and Trademark Office for the development of a new DNA therapy for head and neck cancers. The therapy targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many [...]

Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer

Tuesday, November 17, 2009

0 Comments

Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study [...]

Tag Archive | "EGFR"